Goldman Sachs Maintains Buy on Roivant Sciences, Raises Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins maintains a Buy rating on Roivant Sciences (NASDAQ:ROIV) and raises the price target from $14 to $16.
September 27, 2023 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs maintains a Buy rating on Roivant Sciences and raises the price target from $14 to $16.
The news of Goldman Sachs maintaining a Buy rating and raising the price target for Roivant Sciences is likely to instill confidence in investors and could potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100